PATENT CLAIM ANALYSIS

Application Number: 15986577
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "364000"]

Abstract:
Use of glu-tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).

Claim (Index 29):
The method of  claim 28 , wherein the protein sequence of glu-tubulin is selected from the group consisting of SEQ ID No. 1, SEQ ID 2, SEQ ID 3, SEQ ID 4 and homologues, mutant forms, allelic variants, isoforms, splice variants and proteins with sequences having at least 75% identity to SEQ ID 1, SEQ ID 2, SEQ ID 3 or SEQ ID 4, with the proviso that glutamate is the final amino acid at the C terminal of the protein.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.43333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13980208', '13983887', '15294157', '13979955', '14005680']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8786184661794813
- 35 USC 102 Novelty (BERT): 0.6802977966899071
- Combined Prediction Score: 0.8587863992305238
- Mean Citation Score: 686.2745000000001
- Max Citation Score: 729.4968
- Similarity Product: 659.8210779232979

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test